Prognostic Models for Incident Hypertension: Time to Move from Development to Implementation-An Umbrella Review.
- 1Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Chachapoyas 01001, Peru.
Abstract
Hypertension represents a major modifiable cardiovascular risk factor with increasing global prevalence. While numerous prognostic models for incident hypertension have been developed, their clinical implementation remains limited, suggesting a gap between model development and practical application. This study aimed to synthesize evidence from systematic reviews on multivariable prognostic models estimating the future risk of incident hypertension among initially normotensive individuals, evaluating methodological quality, predictive performance, validation status, calibration reporting, and clinical utility. We conducted an umbrella review, searching six databases from January 2000 to March 2026. Systematic reviews (SRs) evaluating multivariable prognostic models for incident hypertension with documented external validation evidence were included; reviews mixing prognostic and cross-sectional diagnostic screening models were retained only when eligible prognostic evidence could be distinguished and were examined in sensitivity synthesis. Methodological quality was assessed using ROBIS, and primary-study risk of bias was extracted from PROBAST/CHARMS assessments reported by the included reviews. Six SRs (three with meta-analyses) identified 162 unique models reported as prognostic. Models were categorized as traditional statistical (60%), machine learning (30%), and genetic/polygenic risk score-based (10%). Reported pooled AUCs were 0.78 (95% CI 0.76-0.80) for traditional models and 0.82 (95% CI 0.77-0.86) for machine learning models, but all quantitative summaries showed extreme heterogeneity (I² > 99%) and should therefore be interpreted descriptively rather than as stable estimates of clinical performance. Only 21 of 94 models with extractable validation information (22%) underwent at least one external validation, and only seven of 162 unique models were externally validated more than once. Calibration was reported in a minority of models, and no published clinical-impact studies evaluating the use of these models in routine practice were identified. The field should avoid prioritizing additional de novo model derivation in already well-represented settings and should redirect resources toward external validation, recalibration, clinical-impact evaluation, and implementation of the most robust existing models in primary care.
Related
- Development and validation of novel prognostic hepatic-cardiac index and hemodynamic prediction models in pre-capillary pulmonary hypertension patients
- Physical activity and incident hypertension in relation to anthropometric and liver-related indices during 5-year follow-up in the Azar Cohort Study
- Cumulative Burden of Prediabetes, Subclinical Myocardial Injury, and Myocardial Stress and Risk of Incident Atrial Fibrillation in Adults With Hypertension
- Long‐COVID Associated With Incident Hypertension: A Population‐Based Cohort Study
- Conventional and novel hypoxemia-related indices for obstructive sleep apnea severity and incident hypertension: a prospective cohort study.
BibTeX
@article{veraponce2026prognostic,
title = {{Prognostic Models for Incident Hypertension: Time to Move from Development to Implementation-An Umbrella Review.}},
author = {Víctor Juan Vera-Ponce and Jhosmer Ballena-Caicedo},
journal = {Diagnostics (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/diagnostics16193069},
url = {https://europepmc.org/article/MED/42882225},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prognostic Models for Incident Hypertension: Time to Move from Development to Implementation-An Umbrella Review.
AU - Víctor Juan Vera-Ponce
AU - Jhosmer Ballena-Caicedo
PY - 2026
DA - 2026/09/22
JO - Diagnostics (Basel, Switzerland)
DO - 10.3390/diagnostics16193069
UR - https://europepmc.org/article/MED/42882225
AB - Hypertension represents a major modifiable cardiovascular risk factor with increasing global prevalence. While numerous prognostic models for incident hypertension have been developed, their clinical implementation remains limited, suggesting a gap between model development and practical application. This study aimed to synthesize evidence from systematic reviews on multivariable prognostic models estimating the future risk of incident hypertension among initially normotensive individuals, evaluating methodological quality, predictive performance, validation status, calibration reporting, and clinical utility. We conducted an umbrella review, searching six databases from January 2000 to March 2026. Systematic reviews (SRs) evaluating multivariable prognostic models for incident hypertension with documented external validation evidence were included; reviews mixing prognostic and cross-sectional diagnostic screening models were retained only when eligible prognostic evidence could be distinguished and were examined in sensitivity synthesis. Methodological quality was assessed using ROBIS, and primary-study risk of bias was extracted from PROBAST/CHARMS assessments reported by the included reviews. Six SRs (three with meta-analyses) identified 162 unique models reported as prognostic. Models were categorized as traditional statistical (60%), machine learning (30%), and genetic/polygenic risk score-based (10%). Reported pooled AUCs were 0.78 (95% CI 0.76-0.80) for traditional models and 0.82 (95% CI 0.77-0.86) for machine learning models, but all quantitative summaries showed extreme heterogeneity (I² > 99%) and should therefore be interpreted descriptively rather than as stable estimates of clinical performance. Only 21 of 94 models with extractable validation information (22%) underwent at least one external validation, and only seven of 162 unique models were externally validated more than once. Calibration was reported in a minority of models, and no published clinical-impact studies evaluating the use of these models in routine practice were identified. The field should avoid prioritizing additional de novo model derivation in already well-represented settings and should redirect resources toward external validation, recalibration, clinical-impact evaluation, and implementation of the most robust existing models in primary care.
SN - 2075-4418
ER -